BioSpace News Archive

Anebulo Pharmaceuticals, Inc. today announced the dosing of more than half of the 60 subjects planned in Part A of an ongoing Phase 2 clinical trial at the Centre for Human Drug Research (CHDR) in the Netherlands.

Kiromic BioPharma, Inc. today announces that it has filed a Form 12b-25 with the SEC to obtain a 15-calendar day extension to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2021 (the “2021 Form 10-K”).

Biohaven Pharmaceutical Holding Company Ltd., announced that data from a Phase 1, single-center, open-label study evaluating the excretion of a single dose of rimegepant 75 mg in the human milk of healthy lactating women was published in the peer-reviewed journal, Breastfeeding Medicine, the official journal of the Academy of Breastfeeding Medicine.

Numinus Wellness Inc. will release its financial results for the quarter ended February 28, 2022, after market close on Thursday, April 14, 2022.

Biostage Reports Fourth Quarter and Fiscal Year 2021 Financial Results.

Natera, Inc. announced the results of a study 1 to examine both total and donor-derived cell-free DNA (dd-cfDNA) in kidney transplant recipients hospitalized with COVID-19 using its Prospera™ test to assess disease severity and risk of rejection.

Novocure (NASDAQ: NVCR) announced today that it will report financial results for the first quarter 2022 on Thursday, April 28, 2022, before the U.S. financial markets open.

Today, Bayer held its first ever Breakthrough Innovation Forum, focusing on longer-term opportunities for health and agriculture leveraging emerging technologies.

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events.

Ocugen, Inc. announced that the first patient has been dosed in the Phase 1/2 clinical trial of OCU400.